About Issue 2
The CLL treatment landscape is evolving in Canada. Recent data, funding/drug approval updates, and integration of novel agents have made clinical decisions more complex. To provide context and guidance on how to navigate some of the challenges that specialists face in routine practice, CARE™ Faculty are developing a series of case study discussions.
This issue focuses on management of relapse after up-front chemoimmunotherapy. Profile and discussion content follows.
Other Issues in the Series:
Issue 1 (Parts 1 & 2) explored identification and management of relapse after BTK inhibition. These publications are also available for download.